SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory CLL
October 24, 2019
 · 
4 min read
Drug Development
Clinical Catch-Up for the First Week of July
July 3, 2019
 · 
5 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
April 1, 2019
 · 
11 min read
Policy
TGTX INVESTOR DEADLINE: Rosen Law Firm Reminds TG Therapeutics, Inc. Investors of Important Deadline in Class Action- TGTX
November 2, 2018
 · 
3 min read
Policy
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages TGTX Investors to Contact the Firm
October 9, 2018
 · 
2 min read
Policy
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TG Therapeutics, Inc. (TGTX)
October 4, 2018
 · 
2 min read
Policy
TG Therapeutics (TGTX) Alert: Johnson Fistel Investigates TG Therapeutics, Inc.; Investors Encouraged to Contact the Firm
September 26, 2018
 · 
1 min read
Drug Development
TG Therapeutics and Novimmune Forge $185M Agreement
June 20, 2018
 · 
2 min read
 · 
Alex Keown
Amneal and Impax to Marry, Creating the 5th Larges
Genetown
3 High-Risk Biotechs That Could Pop or Drop in 2018
February 5, 2018
 · 
3 min read
 · 
Mark Terry
FDA Advisory Committee Scheduled to Review Lipocin
Drug Development
TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patients With MS
February 2, 2018
 · 
6 min read
Business
TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies
January 8, 2018
 · 
7 min read
Drug Development
TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting
December 11, 2017
 · 
9 min read
Drug Development
TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
November 27, 2017
 · 
5 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results
November 8, 2017
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
November 6, 2017
 · 
1 min read
Drug Development
TG Therapeutics Announces Additional Updated Results from the Ongoing Phase II Study of TG-1101 (ublituximab) in Patients With MS
October 27, 2017
 · 
6 min read
Load More
JOBS